KAMADA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,119 ILa | +1.05% |
|
+12.89% | -4.85% |
| Jul. 03 | Stifel Initiates Kamada at Buy With $18 Price Target | MT |
| May. 08 | Transcript : Kamada Ltd., Q1 2024 Earnings Call, May 08, 2024 |
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.85% | 326M | - | - | |
| +4.18% | 97.7B | A- | ||
| +4.21% | 41.43B | A- | ||
| -11.86% | 32.85B | B- | ||
| +80.99% | 29.33B | A | ||
| -14.25% | 15.47B | C | ||
| -7.36% | 12.89B | B- | ||
| -13.08% | 11.51B | D+ | ||
| +176.65% | 10.74B | D | ||
| -57.36% | 8.97B | B |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- KMDA Stock
- Ratings Kamada Ltd.
